SUGT1P2: The Potential Drug Target and Biomarker (G728706)

Target Name: SUGT1P2

NCBI ID: G728706

SUGT1P2

Other Name(s): SUGT1 pseudogene 2

SUGT1P2: The Potential Drug Target and Biomarker

SUGT1P2 (SUGT1 pseudogene 2) is a gene that encodes a protein known asSUGT1, which is a key regulator of the T-cell receptor (TCR) signaling pathway. The TCR is a critical element of the immune system, responsible for recognizing and responding to foreign antigens in the body.SUGT1P2 has been identified as a potential drug target and biomarker for several diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

TheSUGT1 Pseudogene 2

SUGT1 is a transmembrane protein that plays a critical role in the development and regulation of T-cells, which are a vital part of the immune system. The protein is expressed in many tissues and cells of the body, including the brain, spinal cord, heart, and testes. It is also highly expressed in various types of cancer, including lung, breast, and ovarian cancer.

SUGT1P2 is a pseudogene that is derived from the last exon of the SUGT1 gene. It is a single-spaced gene that contains 24 amino acid residues. The protein produced bySUGT1P2 has a calculated molecular mass of 34.5 kDa and a calculated pI of 4.8.

TheSUGT1 Pseudogene 2 is expressed in many tissues and cells of the body, including the brain, spinal cord, heart, and testes. It is also highly expressed in various types of cancer, including lung, breast, and ovarian cancer.

The Potential Drug Target

SUGT1P2 has been identified as a potential drug target due to its involvement in the T-cell receptor (TCR) signaling pathway. The TCR is a critical element of the immune system, responsible for recognizing and responding to foreign antigens in the body.SUGT1P2 has been shown to play a key role in regulating the activity of T-cells, including their proliferation, differentiation, and survival.

One of the potential drug targets forSUGT1P2 is the inhibition ofSUGT1P2 function, which has been shown to have anti-tumor effects in various types of cancer. The inhibition ofSUGT1P2 has been shown to reduce the number of cancer cells in various types of models, including cell lines and animal models of cancer.

Another potential drug target forSUGT1P2 is the modulation ofSUGT1P2 expression, which has been shown to have anti-inflammatory effects in various types of diseases, including cancer. The modulation ofSUGT1P2 expression has been shown to reduce the production of pro-inflammatory cytokines, such as TNF-alpha, in various types of models, including cancer cells and animal models of disease.

The Potential Biomarker

SUGT1P2 has also been identified as a potential biomarker for several types of diseases, including cancer. The expression ofSUGT1P2 has been shown to be associated with the development and progression of various types of cancer, including lung, breast, and ovarian cancer.

The expression ofSUGT1P2 has also been shown to be associated with the response to certain types of cancer treatments, including chemotherapy and radiation therapy. The expression ofSUGT1P2 has been shown to be reduced in cancer cells that have been treated with certain types of chemotherapy and radiation therapy, indicating that they may be sensitive to these treatments.

Conclusion

SUGT1P2 is a gene that encodes a protein known asSUGT1, which is a key regulator of the T-cell receptor (TCR) signaling pathway. The TCR is a critical element of the immune system, responsible for recognizing and responding to foreign antigens in the body.SUGT1P2 has been identified as a potential drug target and biomarker for several types of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

The inhibition ofSUGT1P2 function or the modulation ofSUGT1P2 expression may have therapeutic benefits in these diseases. Further research is needed to fully understand the potential ofSUGT1P2 as a drug target and biomarker.

Protein Name: SUGT1 Pseudogene 2

The "SUGT1P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SUGT1P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets